News Pharma must slash rare disease drug prices - patient organis... More rare disease drugs must also be approved, says EURORDIS.
News NICE rejects second Alexion ultra-rare disease drug NHS will not fund Kanuma for rare disease LAL-D.
News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News Alexion drug fails in kidney transplant trial Soliris fails when used to treat post-transplant complications.
News Alexion's new CFO promises to put cash to good use After announcing the shock departure of Alexion's chief executive and chief financial officer yesterday, the company's chairman Leonard Bell quickly named David Brennan, ex-AstraZeneca chie
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.